Rat IgG_2b Isotype Control [Clone 1-2] — Purified in vivo PLATINUM™ Functional Grade

Clone 1-2 does not correspond to any of the commonly used antibody clones or labeling methods in in vivo mouse research, based on the most authoritative published sources and listings of standard clones for mechanistic or therapeutic studies. The established clones frequently referenced for in vivo mouse studies include PD-1 antibody clones RMP1-14, J43, and 29F.1A12, each with distinct properties and validated efficacy in mouse models for cancer and immunotherapy research.

If the reference is to clonal labeling techniques (such as CLoNe for progenitor tracing), the core principle involves the use of genetic or fluorescent labeling to trace the lineage and fate of individual cells or clones within tissues, often via targeted injection or transfection, followed by analysis of clone distribution and morphology at various time points. In such studies, the clone designation (e.g., "clone 1-2") typically refers to a labeled phylogenetic or cell clone rather than an antibody or therapeutic molecule.

• PD-1 Antibody Clones (in cancer/immunotherapy research):

  • Used for blocking PD-1/PD-L1 interactions to enhance anti-tumor immune responses.
  • Widely used for both mechanistic studies and therapeutic intervention in mouse cancer models.
  • Popular clones: RMP1-14 (rat anti-mouse), J43 (hamster anti-mouse), and 29F.1A12 (rat anti-mouse).

• Clonal Tracing Methods (developmental biology/genetic studies):

  • Techniques like CLoNe allow multi-color labeling of single progenitor cells and all their progeny.
  • Enables the study of cell lineage, anatomical features, and patterns of tissue development in vivo, using markers or genetic modification.

If your query refers to a specific antibody, genetic construct, or labeling technique named "clone 1-2," this clone is not recognized among those standard for in vivo mouse experimentation as referenced in the scientific literature. If you can provide more context (e.g., the target antigen, the vendor, or specific application), a more precise answer may be possible. Otherwise, researchers should consult detailed protocols or product datasheets for proper use and identification.

Commonly used antibodies and proteins in research and diagnostics include CD14, CD20, CD34, isocitrate dehydrogenase, B-Raf, epidermal growth factor receptor (EGFR), and therapeutic monoclonal antibodies like rituximab, ocrelizumab, and infliximab. These antibodies often appear together in multiplex experiments or comparative studies.

Key supporting details:

• Research applications: Antibodies against CD markers (such as CD14, CD20, CD34) are frequently used for cell recognition and characterization in assays including ELISA, immunocytochemistry (ICC), western blotting (WB), and flow cytometry (FC).
• Diagnostic targets: Antibodies for isocitrate dehydrogenase, B-Raf, and EGFR are used for quantifying proteins or identifying disease markers in immunohistochemistry (IHC).
• Therapeutics: Common monoclonal antibodies (MAbs) include rituximab (targeting CD20 for lymphoma), ocrelizumab (used in multiple sclerosis), infliximab (targeting TNF for rheumatoid arthritis), nivolumab (anti-PD-1 for melanoma), panitumumab (anti-EGFR for colorectal carcinoma), and daclizumab (for transplant rejection).
• Antibody types used together: Commercial and experimental protocols often involve panels of isotype controls, secondary antibodies (such as anti-mouse or anti-rabbit IgG), and antibodies conjugated to fluorescent or enzymatic labels for detection and multiplexing.

Additional proteins:

• For vaccine studies or immunotherapy, polyclonal antibodies (PAbs) targeting microbial antigens (measles, mumps, rubella, HPV) are combined for broad coverage.
• Frequently paired proteins include antigens recognized by the above antibodies (e.g., recombinant EGFR or PD-1 proteins, viral glycoproteins).

Antibodies and proteins most often used "with" others (as multiplex combinations or controls) depend on the experimental goal: cell phenotyping (multiple CD markers), disease diagnostics (cancer or infection-associated proteins), or immunotherapy panels (various humanized or chimeric MAbs).

Alternative interpretation: If “1-2” in your question refers to specific proteins or antibodies (e.g., polymerase I and II, or immunoglobulin chains 1 and 2), please clarify for a more targeted list.

Key findings from scientific literature on “clone 1-2 citations” relate to two main topics: molecular cloning vector efficiency and the phenomenon of cloned journals.

• Molecular Cloning Efficiency:
  The in-house produced pJET1.2/blunt cloning vector achieves very high cloning efficiency, with 100% of analyzed bacterial colonies containing the desired DNA insert across various fragment sizes (538 bp to ~2.3 kb). The protocol is straightforward, cost-effective, and comparable in performance to commercial alternatives. Importantly, phosphorylation of DNA fragments before ligation is not required, and the process simplifies recombinant clone screening while reducing costs.

• Cloned Journals in Scientific Publishing:
  A study tested two hypotheses regarding “cloned journals” (mirror versions of reputable journals used deceptively to attract publications):

  • Multiple causes drive authors to publish in cloned journals, with substantial agreement (average 79%) among surveyed writers. The strongest motivator is open access at low cost (86% agreement).
  • Authors are highly aware of the negative consequences (average 79% agreement), such as hampering scientific progress and misleading peers, but many proceed regardless for academic credit.

Additional context:

• Cloned journals pose a threat to scientific integrity, attracting more submissions than predatory journals due to their superficial similarity to established publications.

• For molecular cloning, the self-made pJET1.2 vector offers technical advantages (preparation, efficiency) and is used routinely in lab practice, streamlining workflows and lowering barriers to gene cloning experiments.

These findings highlight advances in molecular cloning techniques and pressing concerns around publication ethics in the context of cloned journals.

Dosing regimens of clone 1-2 in mouse models are not standardized and can vary depending on the specific disease model, target antigen, and experimental goal. While direct data for "clone 1-2" are not present in the retrieved sources, evidence from analogous antibody dosing strategies in mice suggests several patterns and considerations:

• Typical Doses: Most in vivo monoclonal antibodies in mice (such as anti–PD-1 and anti–PD-L1 clones) are administered in the range of 100–500??g per mouse, often by intraperitoneal injection.
• Dosing Frequency: Common regimens are every 3–4 days, or 2–3 times per week, tailored to the study type (e.g., tumor, infection, or immunotherapy models).
• Mouse Model Differences: The exact dose and schedule may be adjusted for factors such as mouse strain, age, body weight, the pathology being modeled, and pharmacokinetic properties (e.g., half-life, clearance).

Examples from Comparable Antibodies:

• Anti–PD-1 (RMP1-14): 200–500??g/mouse, every 3–4 days, often in cancer models.
• Anti–PD-L1 (10F.9G2): 100–250??g/mouse, 2–3 times per week.
• Pharmacokinetic Modeling: When matching mouse exposure to human therapeutic targets ("humanized" regimens), total daily doses can be divided based on antibody clearance and the specific disease model (e.g., bloodstream vs. lung infection), potentially resulting in split daily dosing to ensure comparable drug exposures.

Model-Specific Adaptations:

• Dosing may be increased or divided for models with faster antibody clearance, such as in acute infection or systemic inflammation.
• In vaccine studies (using mRNA or protein), dosing intervals (prime/boost) range from 3–8 weeks, with longer intervals often yielding stronger and more durable immune responses.

If "clone 1-2" refers to a specific, commercially available research antibody, its optimal regimen will closely track those of other widely used monoclonals, with adjustments based on:

• Disease context (e.g., tumor growth vs. acute infection)
• Target tissue/compartment (e.g., systemic vs. localized models)
• Mouse strain or genetic background

Summary Table: Analogous Antibody Dosing Regimens

In the absence of direct data for clone 1-2, consult published research on the specific clone and adjust according to experimental needs, using the above as a guide. Always consider species-matching, Fc-mediated effects, and the pathology in your model. If you have a particular indication or model in mind, more tailored advice may be available.